In the BioHarmony Drug Report Database

"Preview" Icon

Risankizumab-rzaa

Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.

 

Trade Name

 

Skyrizi
 

Common Name

 

risankizumab
 

ChEMBL ID

 

CHEMBL3990029
 

Indication

 

psoriasis
 

Drug Class

 

Monoclonal antibodies: humanized, interleukins as target

Image (chem structure or protein)

Risankizumab-rzaa structure rendering